AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

Overview of attention for article published in Lancet Neurology, April 2011

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 5 news outlets
blogs: 5 blogs
policy: 2 policy sources
twitter: 8 X users
patent: 11 patents

facebook: 3 Facebook pages
wikipedia: 23 Wikipedia pages
reddit: 1 Redditor
f1000: 2 research highlight platforms

Readers on

mendeley: 723 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 2 policy documents that reference this research output.

Horizon Scan Roundup — 2019

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 26 Feb 2020

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Study on the regulation of advanced therapies in selected jurisdictions

Cited by The Publications Office of the European Union on 06 Dec 2016

The Publications Office of the European Union (Publications Office), based in Luxembourg, is an interinstitutional office whose task is to publish the publications of the institutions of the European Union.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.